Gt biopharma to present at upcoming september investor conferences

Beverly hills, calif., sept. 8, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® protein biologic technology platform, announced today that anthony cataldo, chairman & ceo,  dr. greg berk, president of r&d and chief medical officer, and dr. jeff miller, consulting chief scientific officer will be presenting and hosting one-on-one meetings at the upcoming h.c.
GTBP Ratings Summary
GTBP Quant Ranking